CLINICAL_TRIALS
trial_result
· 2013-12-12
Clinical Trial Update: Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer [Phase 2]
Summary
Phase 2 trial evaluating monthly intramuscular degarelix dosing in patients with prostate cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ferring Pharmaceuticals | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED